LRP1 and epilepsy: Wu et al. reported another novel nanoparticle designed with angiopep-2, a 19-mer peptide with high affinity to the low-density lipoprotein receptor-related protein 1 on the blood–brain barrier, achieving higher concentrations of antiseizure medications and better seizure control in different animal models of epilepsy [103].